EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieStudienprotokollOpen Access · CC BY 4.0

Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial

Zilin Xu iD, Yuanyuan Liu iD, Yanbo Huang iD, Yuzhang Bei iD, Yong He iD, Yanling Li iD, Hao Wang iD, Lingling Meng iD, Le Gao iD, Yan Li iD, Yuhang Cao iD, Lan Liu iD und 3 weitere

European Stroke Journal · 2026

DOI: 10.1093/esj/aakag119 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, 2026. Verfasst von Zilin Xu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Endovascular Procedures, Albumins, Ischemic Stroke, Stroke. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Natural Science Foundation, Ministry of Education of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endovascular therapy is the standard of care for eligible patients with acute ischemic stroke due to LVO. However, nearly half of patients remain functionally dependent even after successful reperfusion. Albumin is a biologically plausible adjunctive cerebroprotective therapy and has shown neuroprotective effects in preclinical studies, but the clinical benefit of albumin combined with EVT remains uncertain. Study design Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2) is an investigator-initiated, prospective, multicenter, randomised, open-label, controlled trial with blinded endpoint assessment (PROBE design). Eligible participants will be randomly assigned in a 1:1 ratio to receive either EVT plus intravenous 25% albumin at 0.5 g/kg (maximum dose, 37.5 g) initiated within 60 min after randomisation and then repeated once daily on days 2–4, or EVT alone. The initial target sample size is 1192 participants (596 per group). A prespecified adaptive sample size re-estimation will be performed after approximately 50% of participants have completed the 90-day follow-up, allowing the total sample size to be increased, but not reduced, to a maximum of 1788 participants. This trial aims to evaluate the efficacy and safety of albumin administered in combination with EVT in patients with acute ischemic stroke caused by anterior circulation LVO. Study endpoints The primary outcome is a favourable functional outcome at 90 days, defined as a mRS score of 0–2, or return to the premorbid mRS for participants with a prestroke mRS score of 3–4. Summary The ARISE-2 trial is designed to evaluate the efficacy and safety of moderate-dose albumin combined with EVT in participants with acute ischemic stroke caused by anterior circulation LVO. The trial will provide evidence on whether albumin can improve functional outcomes as an adjunctive cerebroprotective strategy in patients undergoing reperfusion therapy.

Trial registration

ClinicalTrials.gov: NCT07263308.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endovascular ProceduresAlbuminsIschemic StrokeStrokeNeuroprotective AgentsHumansRandomized Controlled Trials as TopicProspective StudiesMulticenter Studies as TopicTreatment OutcomeMaleFemale

Stichwörter der Autor:innen

Chinaacute ischemic strokeacute large vessel occlusive strokealbuminendovascular therapy

Substanzen

AlbuminsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Department of Neurology, People's Hospital of Huazhou, Maoming, China.
  • Department of Neurology, Liuyang Jili Hospital, Liuyang, China.
  • Department of Neurology, Shenqiu County People's Hospital, Zhoukou, China.
  • Department of Neurology, Linyi City People Hospital, Linyi, China.
  • Department of Neurology, Zhongmu County People's Hospital, Zhengzhou, China.

ORCID-Profile: Zilin Xu, Yuanyuan Liu, Yanbo Huang, Yuzhang Bei, Yong He, Yanling Li, Hao Wang, Lingling Meng, Le Gao, Yan Li, Yuhang Cao, Lan Liu, Jinyue Li, Xunming Ji, Chuanjie Wu

Förderung

  • Beijing Natural Science Foundation
  • Ministry of Education of China

Zitieren

APA

Xu, Z., Liu, Y., Huang, Y., Bei, Y., He, Y., Li, Y., Wang, H., Meng, L., Gao, L., Li, Y., Cao, Y., Liu, L., Li, J., Ji, X., & Wu, C. (2026). Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European Stroke Journal. https://doi.org/10.1093/esj/aakag119

Vancouver

Xu Z, Liu Y, Huang Y, Bei Y, He Y, Li Y, et al. Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial. European Stroke Journal. 2026. doi:10.1093/esj/aakag119

BibTeX
@article{Xu2026,
  author = {Xu, Zilin and Liu, Yuanyuan and Huang, Yanbo and Bei, Yuzhang and He, Yong and Li, Yanling and Wang, Hao and Meng, Lingling and Gao, Le and Li, Yan and Cao, Yuhang and Liu, Lan and Li, Jinyue and Ji, Xunming and Wu, Chuanjie},
  title = {Albumin for patients with acute large vessel occlusive stroke undergoing endovascular therapy-2 (ARISE-2): protocol for a randomised controlled trial},
  journal = {European Stroke Journal},
  year = {2026},
  doi = {10.1093/esj/aakag119}
}
Kostenlos starten →